KR20200028966A - Efgr 티로신 키나제의 임상적으로 중요한 돌연변이체의 선택적 억제제 - Google Patents
Efgr 티로신 키나제의 임상적으로 중요한 돌연변이체의 선택적 억제제 Download PDFInfo
- Publication number
- KR20200028966A KR20200028966A KR1020207003387A KR20207003387A KR20200028966A KR 20200028966 A KR20200028966 A KR 20200028966A KR 1020207003387 A KR1020207003387 A KR 1020207003387A KR 20207003387 A KR20207003387 A KR 20207003387A KR 20200028966 A KR20200028966 A KR 20200028966A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- alkoxy
- independently
- cyano
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762528697P | 2017-07-05 | 2017-07-05 | |
| US62/528,697 | 2017-07-05 | ||
| PCT/US2018/040904 WO2019010295A1 (en) | 2017-07-05 | 2018-07-05 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF EGFR TYROSINE KINASE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20200028966A true KR20200028966A (ko) | 2020-03-17 |
Family
ID=64950363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207003387A Withdrawn KR20200028966A (ko) | 2017-07-05 | 2018-07-05 | Efgr 티로신 키나제의 임상적으로 중요한 돌연변이체의 선택적 억제제 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200131176A1 (https=) |
| EP (1) | EP3648753A4 (https=) |
| JP (1) | JP2020526499A (https=) |
| KR (1) | KR20200028966A (https=) |
| CN (1) | CN111093645A (https=) |
| CA (1) | CA3068854A1 (https=) |
| WO (1) | WO2019010295A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3399968B8 (en) | 2016-01-07 | 2021-12-01 | Xuanzhu Biopharmaceutical Co., Ltd. | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase |
| US11352352B2 (en) * | 2017-06-13 | 2022-06-07 | Beijing Adamadle Biotechnology Limited Liability Company | Aminopyrimidine compound, preparation method therefor and use thereof |
| WO2019154177A1 (zh) * | 2018-02-12 | 2019-08-15 | 恩瑞生物医药科技（上海）有限公司 | 嘧啶类化合物、其制备方法及其医药用途 |
| AU2020240382B2 (en) | 2019-03-19 | 2022-08-25 | Voronoi Inc. | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component |
| US12157730B2 (en) | 2019-03-19 | 2024-12-03 | Voronoi Inc. | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| CN111747950B (zh) * | 2019-03-29 | 2024-01-23 | 深圳福沃药业有限公司 | 用于治疗癌症的嘧啶衍生物 |
| WO2020245208A1 (en) | 2019-06-04 | 2020-12-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis |
| ES2969756T3 (es) | 2019-10-03 | 2024-05-22 | Bristol Myers Squibb Co | Indazol carboxamidas como inhibidores de cinasas |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021104305A1 (zh) * | 2019-11-26 | 2021-06-03 | 上海翰森生物医药科技有限公司 | 含氮多环类衍生物抑制剂、其制备方法和应用 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021243596A1 (en) * | 2020-06-03 | 2021-12-09 | InventisBio Co., Ltd. | Aminopyrimidine compounds, preparation methods and uses thereof |
| KR20220085735A (ko) * | 2020-12-14 | 2022-06-22 | 보로노이바이오 주식회사 | 아이소옥사졸리딘 유도체 화합물 및 이의 용도 |
| CN117561254A (zh) * | 2021-04-30 | 2024-02-13 | 苏州浦合医药科技有限公司 | 用于肺癌治疗的嘧啶基氨基苯 |
| CN115667251A (zh) * | 2021-05-17 | 2023-01-31 | 株式会社沃若诺伊生物 | 杂芳基衍生物化合物、及其用途 |
| CN113651800B (zh) * | 2021-09-07 | 2022-08-19 | 山东铂源药业股份有限公司 | 一种甲磺酸奥希替尼的制备方法 |
| CN115650974B (zh) * | 2022-08-04 | 2024-06-18 | 天津大学 | N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-顺式戊二烯酰胺衍生物及应用 |
| WO2024094064A1 (en) * | 2022-11-02 | 2024-05-10 | Suzhou Puhe Biopharma Co., Ltd | Pyrimidinylaminobenzenes for treating lung cancer with distant metastasis |
| CN120035590A (zh) * | 2022-11-03 | 2025-05-23 | 株式会社沃若诺伊 | Egfr抑制剂的延胡索酸盐、酒石酸盐、苹果酸盐和柠檬酸盐 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI546290B (zh) * | 2008-06-27 | 2016-08-21 | 賽基艾維洛米斯研究股份有限公司 | 雜芳基化合物及其用途 |
| CN104860941B (zh) * | 2014-02-25 | 2017-03-22 | 上海海雁医药科技有限公司 | 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 |
| CN113563332B (zh) * | 2014-12-23 | 2024-12-17 | 达纳－法伯癌症研究所公司 | 作为egfr抑制剂的新的嘧啶和治疗病症的方法 |
| EP3399968B8 (en) * | 2016-01-07 | 2021-12-01 | Xuanzhu Biopharmaceutical Co., Ltd. | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase |
| JP6740452B2 (ja) * | 2016-07-26 | 2020-08-12 | 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ，Ｉｎｃ． | プロテインチロシンキナーゼの活性を阻害するためのアミノピリミジン系化合物 |
-
2018
- 2018-07-05 CN CN201880044480.8A patent/CN111093645A/zh active Pending
- 2018-07-05 WO PCT/US2018/040904 patent/WO2019010295A1/en not_active Ceased
- 2018-07-05 JP JP2019572412A patent/JP2020526499A/ja active Pending
- 2018-07-05 CA CA3068854A patent/CA3068854A1/en not_active Abandoned
- 2018-07-05 KR KR1020207003387A patent/KR20200028966A/ko not_active Withdrawn
- 2018-07-05 EP EP18827860.0A patent/EP3648753A4/en not_active Withdrawn
- 2018-07-05 US US16/628,831 patent/US20200131176A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020526499A (ja) | 2020-08-31 |
| CA3068854A1 (en) | 2019-01-10 |
| WO2019010295A1 (en) | 2019-01-10 |
| US20200131176A1 (en) | 2020-04-30 |
| CN111093645A (zh) | 2020-05-01 |
| EP3648753A4 (en) | 2021-03-17 |
| EP3648753A1 (en) | 2020-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20200028966A (ko) | Efgr 티로신 키나제의 임상적으로 중요한 돌연변이체의 선택적 억제제 | |
| EP3399968B1 (en) | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase | |
| JP7834804B2 (ja) | Ｔａｍ阻害剤としてのピロロトリアジン化合物 | |
| JP6869947B2 (ja) | 置換キナゾリン化合物ならびにそのｇ１２ｃ変異ｋｒａｓ、ｈｒａｓおよび／またはｎｒａｓタンパク質の阻害剤としての使用 | |
| JP6254169B2 (ja) | ベンズアミドおよびヘテロベンズアミド化合物 | |
| RS64655B1 (sr) | Derivati 2,3-dihidro-1h-pirolo[3,4-c]piridin-1-ona kao hpk1 inhibitori za tretman kancera | |
| CN107922431A (zh) | Hpk1抑制剂及其使用方法 | |
| CN114394966A (zh) | 吡啶并嘧啶酮cdk2/4/6抑制剂 | |
| BR112020003254A2 (pt) | moduladores da piruvato quinase e uso destes | |
| CN102459187A (zh) | Janus激酶抑制化合物和方法 | |
| CN115698004A (zh) | 作为hpk1抑制剂的氮杂内酰胺化合物 | |
| TW202116734A (zh) | 乙醯輔酶a合成酶短鏈2(acss2)之小分子抑制劑 | |
| JP2022505872A (ja) | アデノシン受容体アンタゴニストとしての５－アザインダゾール誘導体 | |
| HK40017966A (en) | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase | |
| CN107056754B (zh) | 内嵌脲类结构的wnt通路抑制剂 | |
| TW202005967A (zh) | Ｅｇｆｒ酪胺酸激酶之臨床上重要的突變體之選擇性抑制劑 | |
| RU2819642C1 (ru) | Соединения азалактама в качестве ингибиторов hpk1 | |
| HK40084694A (en) | Azalactam compounds as hpk1 inhibitors | |
| HK40004229B (zh) | Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂 | |
| HK40057478B (zh) | Hpk1抑制剂及其使用方法 | |
| HK40004229A (en) | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase | |
| HK40053093A (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
| HK40002986A (zh) | 吡啶并嘧啶酮cdk2/4/6抑制剂 | |
| OA17121A (en) | Macrocyclic derivatives for the treatment of proliferative diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20200205 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210525 Comment text: Request for Examination of Application |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment) Patent event code: PC12021R01D Patent event date: 20220316 |
|
| WITB | Written withdrawal of application |